NICE TA386: Ruxolitinib is recommended as an option for treating disease-related splenomegaly or symptoms in adults with myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis only in people with intermediate-2 or high-risk disease. (Decision date April 2016)
NICE TA921: Ruxolitinib for treating polycythaemia vera. NHSE commissioned. (Decision date - November 2023)
DO NOT PRESCRIBE (DNP):
NICE TA839: For treating acute graft versus host disease refractory to corticosteroids. Terminated appraisal (Decision date - December 2022)
NICE TA840: For treating chronic graft versus host disease refractory to corticosteroids. Terminated appraisal (Decision date - December 2022)
NHSE commissioned
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
